Streetbeat News

Analyst Ratings

LOPE

Barrington Research analyst Alexander Paris maintains an Outperform rating on Grand Canyon Education (NASDAQ:LOPE) and raises the price target from $140 to $150.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:33 pm

ASRT

BWS Financial analyst Hamed Khorsand maintains a 'Buy' rating on Assertio Holdings (NASDAQ:ASRT) but has lowered the price target from $6 to $4.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:32 pm

XRAY

Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on Dentsply Sirona (NASDAQ:XRAY) but lowered the price target from $51 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:30 pm

FNKO

DA Davidson analyst Linda Bolton Weiser maintains a 'Buy' rating on Funko (NASDAQ:FNKO) and raises the price target from $9.5 to $10.5.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:26 pm

GDDY

Piper Sandler analyst Clarke Jeffries has maintained a Neutral rating on GoDaddy (NYSE:GDDY) and raised the price target from $84 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:24 pm

RMAX

JonesTrading analyst Jason Stewart maintains a 'Buy' rating on RE/MAX Holdings (NYSE:RMAX) but has lowered the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:22 pm

BILL

Canaccord Genuity analyst Joseph Vafi maintains a Buy rating on BILL Holdings (NYSE:BILL) but has lowered the price target from $175 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:20 pm

ARHS

Piper Sandler analyst Peter Keith has maintained an Overweight rating on Arhaus (NASDAQ:ARHS) but lowered the price target from $16 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:18 pm

KPTI

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI) but lowered the price target from $7 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:16 pm

REGN

Piper Sandler analyst Christopher Raymond has maintained an 'Overweight' rating on Regeneron Pharmaceuticals and raised the price target from $885 to $895.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 9:14 pm